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AbstrACt
Objectives Presently, those outcomes that should be 
prioritised for chronic obstructive pulmonary disease 
(COPD) exacerbation studies remain unclear. In order to 
coordinate multicentre studies on eosinophilia- driven 
corticosteroid therapy for patients hospitalised for acute 
exacerbation of COPD (AECOPD), we aimed to find 
consensus among experts in the domain regarding the 
prioritisation of outcomes.
Design A modified Delphi study was proposed 
to recognised COPD experts. Two brainstorming 
questionnaires were used to collect potential outcomes. 
Four subsequent rounds of questionnaires were used 
to rank items according to a six- point Likert scale for 
their importance in the protocol, as well as for being the 
primary outcome. Priority outcome criteria were predefined 
as those for which ≥70% of experts indicated that the 
outcome was essential for interpreting study results.
setting COPD exacerbation management in France.
Participants 34 experts recommended by the French 
Language Pulmonology Society were invited to participate. 
Of the latter, 21 experts participated in brainstorming, and 
19 participated in all four ranking rounds.
results 105 outcomes were ranked. Two achieved 
consensus as candidate primary outcomes: (1) treatment 
failure defined as death from any cause or the need 
for intubation and mechanical ventilation, readmission 
because of COPD or intensification of pharmacologic 
therapy, and (2) the time required to meet predefined 
discharge criteria. The 10 secondary priority outcomes 
included survival, time with no sign of improvement, 
episodes of hospitalisation, exacerbation, pneumonia, 
mechanical or non- invasive ventilation and oxygen use, as 
well as comorbidities during the initial hospitalisation.
Conclusions This Delphi consensus project generated 
and prioritised a great many outcomes, documenting 
current expert views concerning a diversity of COPD 
endpoints. Among the latter, 12 reached consensus as 
priority outcomes for evaluating the efficacy of eosinophil- 
driven corticosteroid therapy in AECOPD inpatients.
study registration The eo- Delphi project/protocol was 
registered on 23 January 2018 at https:// osf. io/ 4ahqw/.
bACkgrOunD
In chronic obstructive pulmonary disease 
(COPD), there is no established biomarker 
that strongly correlates with inflammatory 
or degenerative processes affecting lung 
tissue or treatment responses.1 2 Tradition-
ally, the forced expiratory volume in 1 s from 
spirometry is used as a key monitoring tool.3 
strength and limitations of this study
 ► Despite much recent enthusiasm in the domain, this 
is the first initiative addressing consensus for pri-
ority outcomes for eosinophil- guided corticosteroid 
therapy in acute exacerbation of chronic obstructive 
pulmonary disease (COPD) inpatients.
 ► Registration on the Open Science Framework was 
performed prior to data collection, thus ensuring 
methodological transparency.
 ► There was no expert attrition during the four rounds 
of ranking of 105 potential outcomes.
 ► Patient involvement was not integrated in the study 
design, and outcomes important to patients may 
therefore be lacking.
 ► The presented priority outcomes have the advan-
tage of covering both short and longer term time 
frames, being objective in nature and not associat-
ed with added costs beyond careful data recording. 
They are furthermore applicable to all COPD exacer-
bation studies.
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However, pulmonary function measures can be highly 
variable, and repeated measures are often necessary in 
order to reinforce confidence that change with time 
is occurring.2 They also often demonstrate no correla-
tion with patient reported outcomes or symptoms and 
cannot be considered as a surrogate for the latter.2 4 
Furthermore, many COPD outcomes, such as dyspnoea, 
exacerbation rates, physical or exercise capacities or 
general health status have no gold standard. Finally, the 
comorbidities that often accompany COPD can signifi-
cantly influence outcomes and generate population 
heterogeneity.1 This is all- the- more true in the context 
of severe exacerbations requiring hospital admission 
where multiple factors from multiple fields have the 
potential to influence the course and subsequently the 
outcomes of the disease. Given this context, and despite 
several reviews, the development of diverse patient- 
reported outcomes4 5 and the formation of task groups,2 
those outcomes that should be prioritised for COPD 
exacerbation studies remain unclear.
As demonstrated above, the choice of outcomes that 
should be monitored in order to describe treatment 
responses among COPD patients is clearly a subject of 
current debate. In addition, how outcomes are chosen, 
and why, is a key point in drug trial design. When views 
are too narrow, the selected outcomes might apply to only 
one particular group’s interests or needs.6 Often, less 
favourable, difficult- to- assess or heterogeneous outcomes 
are neglected. A literature review2 found an impressive 
number of extremely different main and secondary 
outcomes that have been assessed in acute exacerba-
tions of COPD (AECOPD). Interestingly, outcomes often 
differ between admitting and non- admitting AECOPD. In 
admitted patients, they also differ according to intensive 
care unit (ICU) requirements, but many other modifiers 
are cited, reflecting the varying definitions for COPD 
exacerbation and heterogeneity in management prac-
tices among sites and/or countries. In light of the lack of 
current consensus on COPD outcomes as well as to avoid 
the latter problems, we aimed to use the Delphi process as 
a means to select a priority outcome set for future COPD 
drug trials evaluating the effects of corticosteroid therapy 
within blood eosinophil strata. The results are expected 
to provide main and secondary outcomes that share the 
following properties: (i) to specifically address the ques-
tion being asked, to be free from the bias associated with 
(ii) commercial interests, or from (iii) potentially inter-
fering factors (comorbidities, social issues and depart-
mental singularities) and finally to be feasible, shareable, 
understandable and applicable to everyday practice. Most 
importantly, Delphi processes build consensus that can 
be recognised by physicians and policy/guideline makers 
in the field, which is crucial for investigator adoption of 
a research protocol. Finally, the Delphi process has the 
added advantages of being anonymous (which avoids 
dominance by opinion leaders and peer pressure) and 
applicable to a relatively large number of individuals 
more efficiently than work groups.6
Currently, there is a gap in the literature concerning 
corticosteroid therapy response among COPD inpatients 
as a function of blood eosinophil levels.7–9 The eo- Drive 
trial (https:// osf. io/ 9j7uk/) seeks to fill this gap by 
comparing eosinophilic COPD patients hospitalised for 
acute exacerbation and treated via systemic corticosteroid 
therapy with a similar population treated via placebo. 
Secondarily, the same comparison will be made among 
non- eosinophilic COPD patients. Within this context, 
the objective of the present work was to use the Delphi 
technique among a panel of experts to reach consensus 
for defining priority outcomes for future COPD drug 
trials evaluating the effects of corticosteroid therapy 
within blood eosinophil strata. Though focused on a 
specific domain, the knowledge generated by this exer-
cise provides a study- design- aid likely applicable to any 
COPD treatment efficacy settings involving exacerbating 
populations.
MethODs
Overview of the Delphi method
A series of anonymous, electronically administered ( www. 
surveymonkey. com) questionnaires was sent to a panel of 
experts from the COPD working group at the SPLF (the 
Société de Pneumologie de Langue Française (the French 
Language Pulmonology Society)), thus ensuring appro-
priate knowledge/experience regarding the problem to 
be addressed (figure 1). Each round of questionnaires 
results in a corpus of information that was fed back to the 
panel before performing the subsequent round. The first 
two ‘brainstorming’ questionnaires represent an ‘item- 
collection’ stage and were open in nature (see below). 
The subsequent rounds of ‘ranking’ questionnaires were 
used to prioritise items according to their importance for 
appearing in the protocol, as well as for being a candidate 
primary outcome. Individual outcome ranking continued 
for a maximum of four rounds, or until dropping criteria 
were achieved. A designated study facilitator (CMS) 
organised questionnaire logistics, feedback to partici-
pants, data collection, analysis and writing.
This volunteer- based Delphi study using anonymous 
questionnaires is categorised as not falling under the 
jurisdiction of the ‘Jardé Law’ in France.
Patient and public involvement
There was no patient or public involvement in this study.
the expert panel
French clinicians who were members of the COPD 
working group at the SPLF and who had previously 
published in the domain or who had included COPD 
patients in previous studies were asked to participate. The 
participation list was prepared by the Société de Pneu-
mologie de Langue Française (the French Language 
Pulmonology Society) and not distributed to members in 
order to maximise anonymity.6
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Figure 1 Methodology flow chart for the eo- Delphi project. The expert panel was invited to participate in six sequentially 
administered questionnaires. Only those experts who responded to an invitation were subsequently invited to participate in 
the next questionnaire. The first questionnaire included questions describing the demographics of the expert panel, as well as 
opinion- type questions. It ended with an open- ended brainstorming question. The second questionnaire corresponded to a 
second round of brainstorming. The final four questionnaires were ranking questionnaires, where outcomes proposed by the 
expert panel during the brainstorming process were evaluated according to a Likert scale specifically designed for prioritising 
outcomes in research trials (table 1).
Demographics and opinion questionnaire
The round 1 instrument started with an online demo-
graphic8 and opinion questionnaire (prepared by the 
eo- Drive organising team)(figure 1) that captured data 
for the following variables: age, sex, academic or private 
practice, current position, years of experience in COPD 
management, and contributes to the development 
of local exacerbation management policy (yes/no). 
In addition, the experts were asked how familiar they 
were with GOLD and French national guidelines ques-
tions, and then to use a visual analogue scale (VAS) to 
quantify how often they applied a given guideline (VAS 
ranging from 0 (never) to 100 (all the time)) in their 
practice and then how they would rate that guideline 
(VAS ranging from 0 (completely inadequate) to 100 
(perfect)). Experts were also asked how they rated their 
local hospital discharge criteria (VAS ranging from 
0 (completely inadequate) to 100 (perfect)). Addi-
tional organisational questions beyond the scope of 
the present outcome summary paper were presented, 
the content of and responses to which are summarised 
in online supplementary additional file 1. Question-
naires and related study documents are available on the 
eo- Delphi study registration site: https:// osf. io/ 8f3aj/
brainstorming questionnaires
The round 1 instrument ended by asking partici-
pants to upload responses to the following question: 
‘Which outcomes should be recorded in order to best 
evaluate treatment strategy efficacy, as well as informa-
tive disease monitoring, for the eo- Drive study?’ An open- 
ended question was chosen as the least- biassed means 
of representing the diverse opinions6 likely present 
among experts concerning how best to measure the 
success of corticosteroids for the treatment of COPD 
exacerbations.
The first round of open- ended responses was edited 
for redundancy, English language and homogenisation 
of time frames, grouped by theme or domain, and then 
provided to all participants. A second round of brain-
storming was then performed to allow for new ideas trig-
gered by the first round (figure 1). Responses from the 
second round were edited in the same way as the first 
round, and then provided to all participants.
Item-rating questionnaires
Following the brainstorming process, each outcome 
was separately evaluated by each participant via succes-
sive item- rating questionnaires (figure 1). In each of the 
latter, participants were asked to prioritise the importance 
of each outcome by applying a six- point Likert- type scale 
(table 1). At the end of each round, results were distrib-
uted to participants. Additionally, the previous ranking 
round’s results were embedded within the subsequent 
questionnaire so that participants were sure to have them 
on hand when ranking.
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Table 1 The Likert scale used for prioritising outcomes
Score Likert item
1 This outcome is of no importance or off topic; it should be excluded from the protocol.
2 This outcome is of dubious value; there are minimal reasons for including it in the protocol as a secondary outcome.
3 This outcome is of moderate importance. It should be included in the protocol as a secondary outcome if logistically 
easy to do so.
4 This is an important though non- essential outcome. It has high scientific value. Effort should be made to include it in 
the protocol as a secondary outcome.
5 This is an essential outcome without which our capacity to respond to or interpret the study’s primary objective will be 
compromised; it must be included in the protocol as a secondary outcome.
6 This is an essential outcome without which our capacity to respond to or interpret the study’s primary objective will be 
compromised; it must be included in the protocol as a candidate primary outcome.
Criteria for dropping outcomes at the end of each round of 
item-rating
Outcomes that met at least one of the following criteria 
were not represented for item- rating in a subsequent 
round:
 ► ≥70% of participants indicate the same score.
 ► ≥70% of participants indicate a score ≤2.
the definition of consensus and outcome classifications
Consensus is defined by a ≥70% agreement between 
Delphi participants. This threshold was agreed on prior 
to study commencement because it represents an easy- to- 
calculate, attainable and strong majority vote. As defined 
in our preregistered protocol (https:// osf. io/ 4ahqw/), 
priority outcomes are specifically defined as those for 
which ≥70% of participants indicate a score ≥5. The 
reader should note that this definition allows for 30% 
dissensus among experts in regard to what can be consid-
ered as a ‘priority’ outcome. We additionally define the 
following classes of outcomes:
 ► Important: ≥70% of participants gave a score ≥4 
(excepting those classed as priority outcomes).
 ► Non- essential secondary: ≥70% of participants gave 
a score of ≥3 (excepting those classed as priority or 
important outcomes).
 ► Lacking importance: ≥70% of participants gave a 
score ≤3 (excepting those classed as non- essential 
secondary or excluded outcomes).
 ► Excluded: ≥70% of participants gave a score ≤2.
 ► Controversial: those outcomes not falling into one of 
the previous classes.
Information provided to participants before round 1
The facilitator contacted each invited participant before 
round 1. The goal was to raise awareness for the study. 
Investigators are busy, and likely discard most surveys. 
Individual contact was initiated to help avoid this kind 
of problem. The facilitator also provided information 
concerning the study rational, design (ie, the study 
protocol) and associated articles for (non- obligatory) 
background reading to each participant.
Minimising participant attrition
As consensus forms, participants with minority opinions 
can become discouraged and tend to drop out of the 
process, resulting in an overestimation of consensus.6 
To avoid this, only participants who completed the final 
questionnaire (and therefore all questionnaires) were 
eligible for authorship.6 Persons who did not respond to 
a questionnaire despite the best efforts of the facilitator 
to encourage participation were not solicited for the next 
round of questionnaires.
Descriptive statistics
Statistical analysis was performed using the R program-
ming environment V.3.3.0 (R Core Team 2016). Centrality 
statistics for quantitative demographic variables (table 2) 
with normal distributions according to Shapiro- Wilks tests 
are given as means±SD. Other quantitative variables (VAS 
scores) are summarised as medians followed by the asso-
ciated IQR, and qualitative ones as numbers and percent-
ages. Prioritised outcomes were ordered according to 
their final mean rank.
results
Participation
Between 23 January and 16 February 2018, 21 out of 
34 invited COPD experts completed the first demo-
graphics/opinions questionnaire and provided a list of 
outcomes that they would like to see evaluated by their 
peers (figure 1). The remaining 13 failed to respond to 
multiple participation requests from the study facilitator. 
The participants were on average 50.67±8.16 years old 
with over 20 years of experience in COPD management 
and the vast majority were men working in a University 
Hospital; 71.43% of participants had achieved professor-
ship (table 2).
Nineteen out of 21 experts (two did not respond to 
multiple invitations to continue to the next round) 
further completed brainstorming round 2 and subse-
quent minor additions were made to the list of outcomes. 
The same 19 experts participated in ranking rounds 1 to 
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Figure 2 COPD expert opinions concerning current guidelines (GOLD in gold and French national guidelines (SPLF) in blue) 
as well as local hospital discharge criteria (light grey). Panel A: %Response rates when asked how familiar experts were with a 
given guideline. Panel B: Visual analogue scale scores for how often experts applied a given guideline (ranging from 0 (never) to 
100 (all the time)) in their practice and then how they would rate that guideline (score ranging from 0 (completely inadequate) to 
100 (perfect)). Experts were also asked how they rated their local hospital discharge criteria (score ranging from 0 (completely 
inadequate) to 100 (perfect)). Medians are presented as horizontal lines, first to third quartiles as boxes, 1.5× the IQR as 
whiskers and outliers as points. COPD, chronic obstructive pulmonary disease; SPLF, the Société de Pneumologie de Langue 
Française.
Table 2 Descriptive statistics for eo- Delphi participants
Completed brainstorming round 1
n = 21
Completed brainstorming round 2 
and ranking rounds 1–4
n = 19
Age (years) 50.67±8.16 51.05±8.51
Gender: male 18 (85.71%) 16 (84.21%)
University Hospital 20 (95.24%) 18 (94.74%)
  Professor 15 (71.43%) 13 (68.42%)
  Assistant professor 1 (4.76%) 1 (5.26%)
  Research MD 1 (4.76%) 1 (5.26%)
  Head of department 8 (38.10%) 8 (42.11%)
  Head of group of departments 1 (4.76%) 1 (5.26%)
  Scientist (PhD) 1 (4.76%) 1 (5.26%)
  Part- time with private practice 1 (4.76%) 1 (5.26%)
Private practice only 1 (4.76%) 1 (5.26%)
Years of experience in COPD management 22.00±8.26 22.26±8.62
Helps develop local exacerbation 
management policy
6 (28.57%) 5 (26.32%)
COPD, chronic obstructive pulmonary disease.
4 (figure 1), which ended on 7 March, 29 March, 27 April 
and 4 July 2018, respectively.
The research experience of the 19 final participants was 
high, with 84.20% indicating research positions (73.68% 
university professors or assistant professors, plus one 
research MD and one scientist). Nearly half (47.37%) 
were in leadership positions (head of department) in 
their respective hospitals, but only 26% indicated that 
they were involved in the development of local exacer-
bation management policy. Their average number of 
years of COPD management experience was 22.26±8.62, 
further reinforcing the high level of appropriate exper-
tise for the group.
expert opinions concerning current guidelines and local 
hospital discharge criteria
As concerns current guidelines, over 95% of the expert 
panel indicated that they were either familiar or very 
familiar with both GOLD and French (SPLF) guidelines 
(see figure 2A). VAS scores indicate that experts apply 
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guidelines a majority of the time, but not always. They 
generally rate guidelines quite well, with slightly higher 
ratings for French guidelines compared with GOLD 
(see figure 2B). In comparison, experts rated their local 
hospital discharge criteria at a median score of 60 (IQR 
of 50–74; see figure 2B), suggesting some room for 
improvement.
Outcomes
Raw and summarised outcome lists resulting from brain-
storming rounds 1 and 2 are available at the study regis-
tration site: https:// osf. io/ 8f3aj/. Among the suggested 
outcomes raised during brainstorming, we set aside 
those that were obviously baseline characteristics; the 
latter sort were noted, but not subjected to prioritisation. 
Many outcomes were of a type associated with survival or 
recurrent event analysis (eg, time to first exacerbation, 
days alive and free from hospitalisation, exacerbation 
frequency), and data collection would have involved 
recording the beginning and end dates/times for an 
event (or a series of events, like exacerbations or hospi-
talisations). The latter types of outcomes were grouped 
together under the label ‘event tracking’, since they share 
common data set structures.
The final ranking round results are presented in online 
supplementary additional file 2, arranged from highest 
mean ranking to lowest mean ranking. Some of the 
proposed outcomes are quite specific, and the reader is 
encouraged to refer to online supplementary additional 
file 2 for outcome details.
Priority outcomes
Priority outcomes are considered by a strong majority 
(≥70%) of Delphi participants to be essential (table 1). 
Their absence from eo- Drive would compromise the inves-
tigators’ capacity to respond to or interpret the study’s 
primary objective (therapeutic efficacy of corticosteroids 
for the treatment of inpatient COPD exacerbation). The 
priority outcome set for the eo- Drive study is presented 
in table 3. Two achieved consensus as candidates for 
a primary outcome: (1) treatment failure according 
to Niewoehner et al,10 which was the outcome with the 
highest mean rank (mean rank of 5.68, online supple-
mentary additional file 2), and (2) the time required 
to meet predefined discharge criteria during the initial 
hospitalisation (mean rank of 5.58, online supplemen-
tary additional file 2). Ranking scores for survival were 
split between primary versus secondary essential outcome 
status, and the remaining priority outcomes reached 
consensus as essential secondary outcomes.
DIsCussIOn
In this six- round (two rounds of brainstorming for 
generating an outcome list plus four rounds of outcome 
ranking) Delphi process involving 21 COPD experts 
and representing 11 University hospitals, one private- 
not- for- profit hospital and two private medical centres, 
consensus was achieved for a priority outcome set for the 
evaluation of eosinophil- guided corticosteroid therapy 
in patients hospitalised for a COPD exacerbation. Given 
the increasing interest in eosinophil- driven treatment for 
COPD patients, and the fact that COPD management 
guidelines currently call for further prospective trials 
with eosinophil stratification to widen the appropriate 
evidence base,7 8 this consensus is timely. The resulting 
priority outcome set is also applicable to other COPD 
exacerbation studies outside the eosinophil- related 
context.
Participation rates from the highly experienced panel 
were excellent, with a 100% retention rate throughout the 
ranking process. Of note, 105 outcomes were proposed 
for prioritisation, and this generous brainstorming 
component demonstrates the importance of conducting 
Delphi exercises in order to maximise the likelihood for 
a multicentre clinical trial to appropriately and accurately 
answer a precise therapeutic question while meeting the 
expectations of multiple researchers. Finally, a subset of 
12 proposed outcomes reached consensus among the 
expert panel as priority outcomes without which the eval-
uation of the therapeutic efficacy of eosinophil- driven 
corticosteroid therapy for severe AECOPD was consid-
ered as compromised (see table 3).
The highest- ranking priority- outcome in the present 
study is a composite- measure of treatment failure 
(table 3). Treatment failure is also the first critical outcome 
indicated by a European Respiratory Society/American 
Thoracic Society (ERS/ATS) task force providing guide-
lines on COPD exacerbation management and addressing 
questions on corticosteroid therapy efficacy in out- patient 
(general efficacy) and in- patient (intravenous vs oral corti-
costeroids) contexts.9 This choice of primary outcome is 
therefore well poised for impacting future guidelines and 
practice. In addition, approximately 1/3 of previously 
published clinical trials on COPD exacerbation report 
results for treatment failure,8 thus assuring a high degree 
of comparability with previous studies. Specific, recently 
influential examples include studies by Bafadhel et al, first 
comparing eosinophil- driven to systematic corticosteroid 
therapy in ambulatory patients (with treatment failure 
differences of 5% vs 13%, respectively),11 and second a 
letter12 describing a 55% difference in treatment failure 
rates when retrospectively comparing corticosteroid 
therapy versus placebo among patients with higher eosin-
ophil counts.
Care must be taken, however, when defining the 
composite elements of treatment failure, as considerable 
variation in definitions has been noted.13 The composite 
measure of treatment failure proposed by the ERS/ATS 
task force included death, admission to the ICU, readmis-
sion to the ICU due to COPD or intensification of phar-
macological therapy.9 The latter is extremely close to the 
definition of treatment failure retained by the present 
paper (table 3) and first defined by Niewoehner et al,10 
easily allowing for integration into future task force initia-
tives. The eo- Drive priority outcome set also provides for 
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Treatment failure (according to Niewoehner et al10) defined as death from any cause or 
the need for intubation and mechanical ventilation, readmission because of COPD or 
intensification of pharmacologic therapy†¶
5.68 94.74




Treatment failure defined as the need to start or repeat treatment within 30 days of 
randomisation§††
5.00 84.21
Episodes* of mechanical ventilation§†† 4.95 94.74
Episodes* of oxygen use§†† 4.95 89.47
Episodes* of non- invasive ventilation§†† 4.84 84.21
The presence/absence of comorbidities/steroid side effects during the initial hospitalisation (at 
admission and discharge)§††
4.74 78.95
Episodes* of exacerbation (distinguishing mild to moderate exacerbations (requiring 
antibiotics and/or de novo/increased oral steroids) and severe exacerbations (requiring 
hospitalisation or emergency room services))§††
4.74 84.21
Episodes* of pneumonia§†† 4.68 84.21
Hospital stays* (distinguishing intensive care, intermediate care and ward stays)§†† 4.63 73.68
The time to signs of improvement during the initial hospitalisation (SItime)**§¶†† 4.42 73.68
At least 70% of eo- Delphi participants gave a Likert score of 5 (essential secondary outcome) or 6 (essential primary outcome) for each listed 
outcome (%Consensus).
*Episodic outcomes require the recording of the start and finish date for each episode observed throughout the study.
†Consensus as candidate primary priority outcomes.
‡Survival scores were split between primary and secondary priority outcome status.
§Consensus as secondary priority outcomes.
¶Niewoehner et al10 define intensification of pharmacologic therapy as the prescription of open- label systemic glucocorticoids, high- dose 
inhaled glucocorticoids (more than eight puffs per day oftriamcinolone acetonide or its equivalent), theophylline or any combination ofthese 
three therapies.
**The predefined discharge ability criteria in eo- Drive are: acidosis has normalised; symptoms have improved to a level compatible with 
discharge; capable of performing minimal daily living activities. The earliest occurring of the latter will be used to determine SItime.
††These outcomes can be biased by competing risks, namely mortality. Care should therefore be taken when aggregating them, and the 
complement (eg days alive and without the outcome in question) thus considered to avoid this bias. Alternatively, competing- risk analyses 
may be required.
COPD, chronic obstructive pulmonary disease.
a simpler treatment failure definition based uniquely on 
treatment recurrence as a secondary outcome (table 3); 
this will enable comparisons with national database 
prescription information in France where the future trial 
will take place (https:// osf. io/ 8f3aj/). In addition to the 
individual elements composing a composite measure of 
treatment failure, their use should also be juxtaposed with 
how patients’ preferences in terms of end- of- treatment 
options are locally taken into account. The latter may 
include choices that result in the non- transfer to an ICU 
or a lack of mechanical ventilation (eg), even though one 
or both were indicated.
The previously mentioned ERS/ATS task force further 
indicated mortality, hospital readmission, length of stay 
(LOS) and time to next exacerbation as critical outcomes 
(with adverse events as an ‘important’ outcome) for 
guiding treatment recommendations in an inpatient 
context (in their case, comparing intravenous and oral 
corticosteroid therapies).9 In comparison, the priority 
outcome set selected during the present study incorporate 
all the previous, and further requires additional informa-
tion. For example, within an initial hospitalisation time 
frame, time to signs of improvement (SItime) and discharge-
ability (DCtime) were considered as essential outcomes, 
rather than just LOS. In a simple scenario, once a patient 
improves and meets discharge criteria, he/she can theo-
retically leave the hospital, and DCtime should approach 
LOS. However, in many domains, meeting predefined 
discharge criteria does not always lead to actual hospital 
discharge due to interference from comorbidities, social 
issues, the availability of appropriate rehabilitation or 
care facilities14 or individual hospital cluster effects.15 
The proposed DCtime variable should therefore have fewer 
sources of heterogeneity as compared with LOS (though it 
also requires more data capture). Finally, immediate- time- 
frame outcomes may be particularly short for eosinophilic 
groups receiving corticosteroid therapy as compared with 
non- eosinophilic or placebo groups.16 It is not surprising 
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then that the eo- Delphi expert panel indicated DCtime as a 
second candidate primary outcome for future studies on 
eosinophil- driven corticosteroid therapy.
A limitation of the present study is the lack of patient 
involvement during study design and deployment. The 
presented outcomes therefore represent the physicians’ 
point of view only, and outcomes important to patients 
may be lacking. The definition of consensus also allowed 
for up to 30% dissensus when classifying outcomes, and 
the reader is thus encouraged to refer to online supple-
mentary additional file 2 as the distribution of dissensus 
votes over ranks can be quite variable and informative. A 
further limitation of this study is the lack of a literature 
review for gathering further outcomes.
A major methodological consideration that should be 
given thought when using the outcomes in table 3 is the 
potential for competing risks, namely mortality. To avoid 
this source of bias, variables of the type ‘days alive and 
free from hospitalisation’, which take the complement 
of time spent in a given event, can be used when aggre-
gating episode- type or duration- type data. This effectively 
replaces mortality- affected measures with low values 
and avoids the related competing risk bias. Alternatively 
(especially when the latter is not possible), competing 
risk analyses can be employed during a sensitivity evalua-
tion (as classically performed for survival- type analyses) to 
explore potential impacts on results.
The reader should also note that specific time frames 
are not consistently enforced as a result of this outcome- 
prioritising Delphi study, which was performed early- on 
during a study- design process. Because the future eo- Drive 
study has a follow- up time of 3 months, the latter is the 
suggested time frame unless otherwise specified. Because 
time frame variation is a source of heterogeneity in the 
literature, study designers should carefully choose time 
frames to maximise clinical validity and comparisons 
with past studies. Further guidance on time frames is also 
likely upcoming, with the anticipated development of a 
core outcome set for AECOPD (http://www. comet- initia-
tive. org/ Studies/ Details/ 1325).
Despite the above limitations, the presented priority 
outcome set has the advantages of being objective in 
nature, applicable to any COPD exacerbation study and 
not associated with added costs beyond careful data 
recording. Specifically, obtaining high- quality survival 
or episode data requires effort by data- capture teams 
and maintained contact with patients and/or their care 
providers. These data types can give rise to numerous 
useful measures, such as ‘time to next event’, mean 
cumulative functions for recurrent events17 and event 
numbers/rates. The most recent eosinophil- driven corti-
costeroid therapy study in COPD by Sivapalan et al used 
the number of days alive and out of hospital within 14 
days after recruitment as their primary outcome.16 The 
hospital episode data collected during eo- Drive will provide 
the means for a comparison with the latter by using each 
day a patient is alive and out of the hospital as a cumula-
tive recurrent event plotted against time.17
Interestingly, though asked to consider an eosinophil- 
guided corticoid therapy context, simultaneous changes 
in blood eosinophilia did not reach consensus as a 
priority outcome, but were classified as non- essential 
secondary outcomes (online supplementary additional 
file 2), suggesting that changes in this biomarker were 
not considered as essential for interpretation of results. 
This may be because experts were strictly considering 
the evaluation of treatment efficacy, without exploring 
associated potential mechanisms. It may also suggest that 
certain experts do not consider eosinophilia to be a perti-
nent mechanism of disease for many COPD patients.
Conclusions
In conclusion, if given the opportunity, collaborating 
investigators will provide a plethora of information 
concerning outcome expectations for a given clinical 
research project. In the present study, the Delphi process 
proved efficient for drawing consensus and team feder-
ation for the project. The resulting set of 12 priority 
outcomes appear logical, objective, feasible and repro-
ducible vis-à-vis efficacy testing for eosinophil- driven 
corticosteroid therapy strategies in patients hospitalised 
for AECOPD, and furthermore applicable to COPD 
exacerbation studies in general. Finally, the ranking 
exercise documents current knowledge among investiga-
tors concerning a wide range of outcomes, providing a 
valuable tool for COPD study designers and students of 
methodology.
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